Seladelpar treatment of patients with primary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival Seladelpar treatment over 2 years resulted in a sustained
Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL
More than just an itch: Impact of cholestatic pruritus in primary biliary cholangitis (PBC) on health-related quality of life (HRQoL) Cholestatic pruritus (particularly severe pruritus) has a significant negative impact
Home-based exercise in patients with refractory fatigue associated primary biliary cholangitis: final results from the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) clinical trial A 12-wk individualized HBEP, incorporating resistance
A randomized control trial evaluating the impact of a web-based mind-body wellness intervention for patients with primary biliary cholangitis This 12-week intervention improved measures of mental wellness and quality of life.